Moreover, since several studies have pointed to impairments in the cell death processes in neurodegenerative diseases and that intervention in this mechanistic pathway seems to be a promising therapeutic strategy, further investigation of the differences in mTOR and FoxO3a activity between the sexes may also contribute to a sex-specific target for drug development. Here, FOXO3 is linked to neurodegenerative disease.